Skip to content

Study · Non-randomized trial · 2018

6 results

Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.

Sugimoto DH, Dex T, Stager W, Aroda VR

Diabetes, obesity & metabolism24 Jul 2018Cited by 2 (Europe PMC)

PMID29923361 (opens in a new tab)DOI10.1111/dom.13438 (opens in a new tab)PepBankPUB-29923361
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In low-risk LixiLan-L patients with type 2 diabetes, added lixisenatide reduced HbA1c more than insulin glargine alone.

    In plain wordsAdding lixisenatide reduced long-term blood sugar more than insulin glargine alone in the low-risk LixiLan-L subgroup.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, low-risk LixiLan-L subgroup
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reported HbA1c change
    1.1%
    iGlarLixi, sign as printed
    HbA1c change
    −0.6%
    iGlar
    P value
    < 0.001
    comparison

    Source sentences

    Summary
    iGlarLixi was more effective in reducing HbA1c than comparators in both LR and HR patients across the LixiLan-L trial (change from baseline, 1.1% vs -0.6% for iGlar in both groups; P < 0.001)
  2. 02HumanNon-randomized trialEfficacy outcome

    In high-risk LixiLan-L patients with type 2 diabetes, added lixisenatide reduced HbA1c more than insulin glargine alone.

    In plain wordsAdding lixisenatide reduced long-term blood sugar more than insulin glargine alone in the high-risk LixiLan-L subgroup.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, high-risk LixiLan-L subgroup
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reported HbA1c change
    1.1%
    iGlarLixi, sign as printed
    HbA1c change
    −0.6%
    iGlar
    P value
    < 0.001
    comparison

    Source sentences

    Summary
    iGlarLixi was more effective in reducing HbA1c than comparators in both LR and HR patients across the LixiLan-L trial (change from baseline, 1.1% vs -0.6% for iGlar in both groups; P < 0.001)
  3. 03HumanNon-randomized trialEfficacy outcome

    In low-risk LixiLan-O patients with type 2 diabetes, added lixisenatide reduced HbA1c more than insulin glargine alone.

    In plain wordsAdding lixisenatide reduced long-term blood sugar more than insulin glargine alone in the low-risk LixiLan-O subgroup.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, low-risk LixiLan-O subgroup
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −1.6%
    iGlarLixi, low risk
    HbA1c change
    −1.3%
    iGlar, low risk
    P value
    < 0.01
    comparison

    Source sentences

    Summary
    and the LixiLan-O trial (change from baseline, LR/HR -1.6%/-1.4% vs -1.3%/-1.2% for iGlar and -0.8%/-0.9% for lixisenatide; P < 0.01).
  4. 04HumanNon-randomized trialEfficacy outcome

    In high-risk LixiLan-O patients with type 2 diabetes, added lixisenatide reduced HbA1c more than insulin glargine alone.

    In plain wordsAdding lixisenatide reduced long-term blood sugar more than insulin glargine alone in the high-risk LixiLan-O subgroup.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction, high-risk LixiLan-O subgroup
    Study

    n: not reported in source

    Comparator
    Insulin glargine alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −1.4%
    iGlarLixi, high risk
    HbA1c change
    −1.2%
    iGlar, high risk
    P value
    < 0.01
    comparison

    Source sentences

    Summary
    and the LixiLan-O trial (change from baseline, LR/HR -1.6%/-1.4% vs -1.3%/-1.2% for iGlar and -0.8%/-0.9% for lixisenatide; P < 0.01).
  5. 05HumanNon-randomized trialEfficacy outcome

    In low-risk LixiLan-O patients with type 2 diabetes, HbA1c decreased by 0.8% from baseline with lixisenatide alone.

    In plain wordsIn the low-risk subgroup, long-term blood sugar decreased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c change, low-risk lixisenatide-alone subgroup
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −0.8%
    lixisenatide alone, low risk

    Source sentences

    Summary
    and the LixiLan-O trial (change from baseline, LR/HR -1.6%/-1.4% vs -1.3%/-1.2% for iGlar and -0.8%/-0.9% for lixisenatide; P < 0.01).
  6. 06HumanNon-randomized trialEfficacy outcome

    In high-risk LixiLan-O patients with type 2 diabetes, HbA1c decreased by 0.9% from baseline with lixisenatide alone.

    In plain wordsIn the high-risk subgroup, long-term blood sugar decreased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c change, high-risk lixisenatide-alone subgroup
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −0.9%
    lixisenatide alone, high risk

    Source sentences

    Summary
    and the LixiLan-O trial (change from baseline, LR/HR -1.6%/-1.4% vs -1.3%/-1.2% for iGlar and -0.8%/-0.9% for lixisenatide; P < 0.01).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.